API Export of Draflazine obtained from Indian Customs Trade Statistics

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 120770-34-5, R-75231, (s)-draflazine, 1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide, R 75231, R75231
Molecular Formula
C30H33Cl2F2N5O2
Molecular Weight
604.5  g/mol
InChI Key
IWMYIWLIESDFRZ-UHFFFAOYSA-N
FDA UNII
0Y25DT968Y

Draflazine
1 2D Structure

Draflazine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide
2.1.2 InChI
InChI=1S/C30H33Cl2F2N5O2/c31-25-15-23(35)16-26(32)29(25)37-28(40)18-39-14-13-38(17-27(39)30(36)41)12-2-1-3-24(19-4-8-21(33)9-5-19)20-6-10-22(34)11-7-20/h4-11,15-16,24,27H,1-3,12-14,17-18,35H2,(H2,36,41)(H,37,40)
2.1.3 InChI Key
IWMYIWLIESDFRZ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CN(C(CN1CCCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)N)CC(=O)NC4=C(C=C(C=C4Cl)N)Cl
2.2 Other Identifiers
2.2.1 UNII
0Y25DT968Y
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-aminocarbonyl-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)-pentyl)-1-piperazineacetamide

2. R 75 231

3. R 75231

4. R 88 016

5. R 88016

6. R-75231

7. R-88016

8. R75231

2.3.2 Depositor-Supplied Synonyms

1. 120770-34-5

2. R-75231

3. (s)-draflazine

4. 1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide

5. R 75231

6. R75231

7. 0y25dt968y

8. R-70380

9. Draflazinum

10. R70380

11. Draflazina

12. Draflazinum [inn-latin]

13. Draflazina [inn-spanish]

14. Draflazine [usan:inn:ban]

15. Unii-0y25dt968y

16. Draflazine [inn]

17. Draflazine (usan/inn)

18. Draflazine [usan]

19. (+-)-4'-amino-4-(5,5-bis(p-fluorophenyl)pentyl)-2-carbamoyl-2',6'-dichloro-1-piperazineacetanilide

20. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-

21. Schembl215826

22. Gtpl4590

23. Chembl1628717

24. Dtxsid60869655

25. Benzenemethanesulfonylchloride, 2-methyl-

26. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-,(+-)-

27. Db-057830

28. Hy-106841

29. Cs-0026695

30. Ft-0743995

31. D03906

32. Q27077112

33. (+/-)-2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-1-piperazine-acetamide

34. (+/-)-4'-amino-4-(5,5-bis(p-fluorophenyl)pentyl)-2-carbamoyl-2',6'-dichloro-1-piperazineacetanilide

35. 1-{[(4-amino-2,6-dichlorophenyl)carbamoyl]methyl}-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide

36. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-, (+/-)-

37. 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-1-piperazineacetamide

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 604.5 g/mol
Molecular Formula C30H33Cl2F2N5O2
XLogP35.4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count7
Rotatable Bond Count11
Exact Mass603.1979370 g/mol
Monoisotopic Mass603.1979370 g/mol
Topological Polar Surface Area105 Ų
Heavy Atom Count41
Formal Charge0
Complexity810
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Cardiotonic Agents

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)


Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty